Literature DB >> 1749920

Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality.

A Bøyum1, D Løvhaug, L Tresland, E M Nordlie.   

Abstract

This paper briefly reviews commonly used procedures for separation of mononuclear cells (MNC) and granulocytes from human blood with X-ray contrast media as gradient material, and also presents new and modified procedures for leucocyte preparation. Standard techniques for human blood do not always yield satisfactory results with blood from other species. In general pure MNC are easily obtained (top fraction), but often the granulocyte fraction has a low purity, due to contamination with MNC that move to the bottom during centrifugation and contaminate the granulocyte suspension. Obviously the density distribution of MNC differs between species. However, the separation can be improved by fine adjustment of gradient medium osmolality. For this purpose we have used Nycodenz, a non-ionic X-ray contrast medium. A favourable property of Nycodenz solutions is that the osmolality and density can easily be varied over a broad range. The cells react promptly to a change of medium osmolality. In hypertonic medium the cells expel water, shrink, their density increases and they sediment faster, in spite of a smaller radius. Further, the cells may pass what was initially a density barrier. A hypotonic environment has the opposite effect. In the present work we were able to show that a slight change of medium osmolality clearly improved different techniques for separation of leucocyte subgroups. For instance, the Isopaque-Ficoll (IF) technique consistently yielded MNC and granulocytes of high purity with human blood. However, with blood from rabbits, rats and mice the granulocyte suspensions were contaminated by 40-60% MNC. By utilizing Nycodenz, and lowering the osmolality by 10-12 per cent (at constant density--1.077 g/ml) we obtained satisfactory separation of MNC as well as granulocytes with blood from these species. A problem in the routine separation of granulocytes (IF) is a high contamination of erythrocytes (2-5 per cell) in the granulocyte suspension. With a two-layer technique with Nycodenz solutions of different densities it was possible to separate granulocytes almost devoid of erythrocytes, after proper adjustment of osmolality. By appropriate combination of density and osmolality, Nycodenz was a suitable gradient material in other separation procedures as well, e.g. the separation of monocytes and mast cells. To facilitate the use of Nycodenz as a versatile gradient material, a computer program providing recipes for various Nycodenz solutions is included as an appendix.

Entities:  

Mesh:

Year:  1991        PMID: 1749920     DOI: 10.1111/j.1365-3083.1991.tb01594.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  69 in total

1.  An intact cytoskeleton is required for prolonged respiratory burst activity during neutrophil phagocytosis.

Authors:  D Granfeldt; C Dahlgren
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

2.  Proinflammatory activity of a cecropin-like antibacterial peptide from Helicobacter pylori.

Authors:  J Bylund; T Christophe; F Boulay; T Nyström; A Karlsson; C Dahlgren
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  A bactericidal cecropin-A peptide with a stabilized alpha-helical structure possess an increased killing capacity but no proinflammatory activity.

Authors:  Huamei Fu; Ase Björstad; Claes Dahlgren; Johan Bylund
Journal:  Inflammation       Date:  2004-12       Impact factor: 4.092

4.  Interleukin-8-derived peptide has antibacterial activity.

Authors:  Ase Björstad; Huamei Fu; Anna Karlsson; Claes Dahlgren; Johan Bylund
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.

Authors:  Peter G Barlow; Yuexin Li; Thomas S Wilkinson; Dawn M E Bowdish; Y Elaine Lau; Celine Cosseau; Christopher Haslett; A John Simpson; Robert E W Hancock; Donald J Davidson
Journal:  J Leukoc Biol       Date:  2006-06-22       Impact factor: 4.962

6.  The host defense peptide LL-37 selectively permeabilizes apoptotic leukocytes.

Authors:  Ase Björstad; Galia Askarieh; Kelly L Brown; Karin Christenson; Huamei Forsman; Karin Onnheim; Hsin-Ni Li; Susann Teneberg; Olaf Maier; Dick Hoekstra; Claes Dahlgren; Donald J Davidson; Johan Bylund
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Adrenaline-induced leucocytosis: recruitment of blood cells from rat spleen, bone marrow and lymphatics.

Authors:  P O Iversen; A Stokland; B Rolstad; H B Benestad
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1994

8.  Modulation of rat monocyte/macrophage innate functions by increasing intensities of swimming exercise is associated with heat shock protein status.

Authors:  Cinthia Maria Schöler; Claudia Vieira Marques; Gustavo Stumpf da Silva; Thiago Gomes Heck; Lino Pinto de Oliveira Junior; Paulo Ivo Homem de Bittencourt
Journal:  Mol Cell Biochem       Date:  2016-08-13       Impact factor: 3.396

9.  HLA-A01-, -A03-, and -A024-binding nanomeric epitopes in polyomavirus BK large T antigen.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Diana Metes; Marta Bueno; Adriana Zeevi; Ron Shapiro; Raphael Viscidi; Parmjeet S Randhawa
Journal:  Hum Immunol       Date:  2009-05-14       Impact factor: 2.850

10.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.